Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Essentiality of FASII pathway for Staphylococcus aureus.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
    • بيانات النشر:
      Publication: Basingstoke : Nature Publishing Group
      Original Publication: London, Macmillan Journals ltd.
    • الموضوع:
      Fatty Acids/*biosynthesis ; Staphylococcus aureus/*metabolism; Animals ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Bacteremia/drug therapy ; Bacteremia/microbiology ; Bacterial Proteins/antagonists & inhibitors ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Fatty Acids/metabolism ; Fatty Acids/pharmacology ; Host-Pathogen Interactions/drug effects ; Humans ; Mice ; Reproducibility of Results ; Staphylococcal Infections/drug therapy ; Staphylococcal Infections/microbiology ; Staphylococcus aureus/drug effects ; Staphylococcus aureus/genetics ; Staphylococcus aureus/pathogenicity ; Triclosan/pharmacology
    • نبذة مختصرة :
      Recently, Brinster et al. suggested that type II fatty-acid biosynthesis (FASII) is not a suitable antibacterial target for Gram-positive pathogens because they use fatty acids directly from host serum rather than de novo synthesis. Their findings, if confirmed, are relevant for further scientific and financial investments in the development of new drugs targeting FASII. We present here in vitro and in vivo data demonstrating that their observations do not hold for Staphylococcus aureus, a major Gram-positive pathogen causing several human infections. The observed differences among Gram-positive pathogens in FASII reflects heterogeneity either in fatty-acid synthesis or in the capacity for fatty-acid uptake from the environment.
    • Comments:
      Comment on: Nature. 2009 Mar 5;458(7234):83-6. (PMID: 19262672)
    • References:
      Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. (PMID: 17420210)
      J Exp Med. 2001 May 7;193(9):1067-76. (PMID: 11342591)
      Prog Lipid Res. 2001 Nov;40(6):467-97. (PMID: 11591436)
      Nature. 2006 May 18;441(7091):358-61. (PMID: 16710421)
      Nat Med. 2006 Sep;12(9):1027-9. (PMID: 16906155)
      Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24. (PMID: 12234833)
      Nat Rev Microbiol. 2004 Mar;2(3):189-202. (PMID: 15083155)
      Science. 1997 May 2;276(5313):718-25. (PMID: 9115192)
      J Bacteriol. 2007 Nov;189(22):8139-44. (PMID: 17827283)
      Infect Immun. 2005 Dec;73(12):8033-8. (PMID: 16299297)
      Nat Rev Microbiol. 2008 Mar;6(3):222-33. (PMID: 18264115)
      Nature. 2009 Mar 5;458(7234):83-6. (PMID: 19262672)
      Biochem Soc Trans. 2002 Nov;30(Pt 6):1050-5. (PMID: 12440970)
      Methods Enzymol. 1981;72:520-32. (PMID: 7031426)
      FEMS Microbiol Lett. 2004 Feb 16;231(2):177-84. (PMID: 14987762)
    • الرقم المعرف:
      0 (Anti-Bacterial Agents)
      0 (Bacterial Proteins)
      0 (Fatty Acids)
      4NM5039Y5X (Triclosan)
    • الموضوع:
      Date Created: 20100122 Date Completed: 20100303 Latest Revision: 20211020
    • الموضوع:
      20231215
    • الرقم المعرف:
      10.1038/nature08667
    • الرقم المعرف:
      20090698